mechanism of c-met in non-small cell lung cancer and its treatment and testing

Clicks: 252
ID: 134030
2015
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Hepatocyte growth factor/c-MET (HGF/c-MET) signaling pathway can be abnormal activated by many mechanisms such as c-MET mutation, amplification and the overexpression of HGF, and it plays an important role in the development of non-small cell lung cancer (NSCLC), as well as in the tolerance of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in NSCLC. Therefore, c-MET is a new molecular target for the therapy of NSCLC since EGFR and ALK. At present, although the c-MET inhibitors have shown a potential prospect in some clinical trials, its assessment of safety and effectiveness in clinical applications, and the choice of testing methods and standards still need a further discussion. In this paper, we summarized the mechanism of c-MET in NSCLC, as well as its treatment prospect and selection of testing methods.
Reference Key
liang2015chinesemechanism Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Hongge LIANG;Mengzhao WANG
Journal proceedings of the 10th acm multimedia systems conference, mmsys 2019
Year 2015
DOI 10.3779/j.issn.1009-3419.2015.12.06
URL
http://dx.doi.org/10.3779/j.issn.1009-3419.2015.12.06
Keywords
treatment lung neoplasms Oncology including cancer and carcinogens tumors testingneoplasms

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.